Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers and resistance mechanisms of IL-17A inhibitor bimekizumab in hidradenitis suppurativa
ChiCTR2600129782Phase 4Not yet recruiting
- Sponsor
- PLA Air Force Characteristic Medical Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by PLA Air Force Characteristic Medical Center. Primary endpoint: HiSCR50 response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on ChiCTR2600129782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129782.